Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/PTSD

LSD for PTSD

38 papers and 0 clinical trials exploring lsd as a treatment for ptsd.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
Indication354 million people suffering from PTSD globally.

PTSD

Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.

Full PTSD profile

Academic Research

38 papers
Open Accessindividual

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians

This survey study (n=41) examined how Swiss physicians provide psychedelic-assisted therapy under legal exemptions, mainly for depression, anxiety, PTSD and chronic pain. It found wide variation in practice, with psilocybin, MDMA and LSD commonly used, music often played during sessions, and adverse effects usually including disorientation, feeling cold, anxiety and nausea.

Published
May 20, 2026
Journal
Therapeutic Advances in Psychopharmacology
Authors
Beichmann, K., Catzeflis, P., Aicher, H. D., Seragnoli, F., Calder, A., Amrani, A., Hasler, G.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment

This qualitative sub-study (n=21) nested within a Phase II trial found that psilocybin treatment enabled participants with PTSD to engage with trauma-related material both directly and indirectly through affective, somatic, and self-transcendent experiences, contrasting with standard treatments that require direct confrontation with trauma memories.

Published
December 1, 2025
Journal
EClinicalMedicine
Authors
Modlin, N. L., Williamson, V., Goodwin, G. M., Malievskaia, E., Atli, M., Elek, Z., Gaillard, A., Koelpin, D., Cleare, A., Agrawal, M., Yehuda, R., Kirlic, N., Rucker, J.
Paywallindividual

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

This receptor profiling study (n=41 compounds) maps the pharmacological activity of classical psychedelics across 318 human G-protein-coupled receptors and, for LSD, over 450 human kinases. It finds that psychedelics act potently at nearly all serotonin, dopamine, and adrenergic receptors, with multiple 5-HT2A receptor signalling pathways linked to psychedelic effects in vivo.

Published
July 15, 2025
Journal
Neuron
Authors
Jain, M. K., Gumpper, R. H., Slocum, S. T., Gloriam, D. E., Nichols, D. E., Roth, B. L., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C. M., Huang, X. P., Shub, L., Diberto, J. F., Kim, K., Deleon, C., Krumm, B. E., Fay, J. F., Keiser, M., Hauser, A. S., Dror, R. O., Shoichet, B.
Open Accessindividual

Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects

In healthy volunteers, acute MDMA and LSD did not alter within-network connectivity of associative, limbic or sensorimotor striatal seeds but produced distinct striato‑cortical changes: MDMA reduced limbic striatum–amygdala coupling, while LSD increased associative striatum connectivity with frontal, sensorimotor and visual cortices. These drug-specific effects mainly occurred outside standard striatal networks, consistent with reduced network modularity and increased cross‑network connectivity under psychedelics.

Published
February 8, 2025
Journal
Biorxiv
Authors
Ertl, N., Ashraf, I., Azizi, L., Roseman, L., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L., Wall, M. B.
Open Accessmeta

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

This review (2025) of the Swiss limited access scheme describes how approximately 100 physicians treated 723 patients with MDMA, LSD, or psilocybin in 2024, with patients typically receiving 2-4 psychedelic-assisted therapy sessions within 12 months for treatment-resistant conditions.

Published
January 1, 2025
Journal
Neuroscience Applied
Authors
Mueller, F., Hawrot, T., Schmid, Y.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and PTSD yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all PTSD trials Full LSD profile Full PTSD profile